Drug Type Antibody fusion proteins |
Synonyms- |
Target |
Mechanism ACVR2B inhibitors(Activin receptor type-2B inhibitors), ALK4 inhibitors(activin A receptor type 1B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Spinal Muscular Atrophy | Preclinical | US | 15 Feb 2021 |